(Q33414272)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24676877%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

title

A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24676877%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24676877%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Michele Maio

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24676877%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Ana Arance

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24676877%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Paul Lorigan

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24676877%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Jean-Jacques Grob

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24676877%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

10

Axel Hauschild

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24676877%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

author name string

Omid Hamid

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24676877%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Robert Ilaria

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24676877%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Pascal Wolter

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24676877%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Thomas E Hutson

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24676877%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Jeeyun Lee

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24676877%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Peter Mohr

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24676877%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Marjo Hahka-Kemppinen

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24676877%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Christopher Kaiser

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24676877%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

P Kellie Turner

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24676877%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Ilaria Conti

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24676877%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

language of work or name

English

0 references

publication date

26 March 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24676877%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24676877%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

volume

120

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24676877%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

issue

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24676877%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

page(s)

2016-2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24676877%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28635

21 January 2018

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28635

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28635

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28635

Immunotherapy for metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28635

Tasisulam sodium, an antitumor agent that inhibits mitotic progression and induces vascular normalization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28635

Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28635

A phase 2 study of tasisulam sodium (LY573636 sodium) as second-line treatment for patients with unresectable or metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28635

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28635

A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28635

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28635

A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound, administered as a 24-h continuous infusion in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28635

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28635

Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28635

7 January 2021

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28635

7 January 2021

Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28635

7 January 2021

A phase II trial of taxol in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28635

7 January 2021

A phase II study of taxol in patients with malignant melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28635

7 January 2021